Brokerages expect that Endologix, Inc. (NASDAQ:ELGX) will report ($0.22) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Endologix’s earnings, with the lowest EPS estimate coming in at ($0.27) and the highest estimate coming in at ($0.17). Endologix also posted earnings of ($0.22) per share in the same quarter last year. The firm is scheduled to announce its next quarterly earnings report on Wednesday, February 28th.
According to Zacks, analysts expect that Endologix will report full year earnings of ($0.67) per share for the current financial year, with EPS estimates ranging from ($0.91) to ($0.56). For the next fiscal year, analysts forecast that the company will report earnings of ($0.56) per share, with EPS estimates ranging from ($0.84) to ($0.45). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Endologix.
A number of brokerages recently commented on ELGX. Canaccord Genuity reiterated a “hold” rating and set a $5.00 price objective on shares of Endologix in a research report on Monday, October 9th. Stifel Nicolaus set a $6.00 price objective on Endologix and gave the stock a “hold” rating in a research report on Friday, October 6th. Royal Bank of Canada reiterated a “hold” rating and set a $5.00 price objective on shares of Endologix in a research report on Tuesday, October 3rd. BidaskClub downgraded Endologix from a “buy” rating to a “hold” rating in a research report on Friday, December 15th. Finally, Piper Jaffray Companies reiterated an “overweight” rating on shares of Endologix in a research report on Tuesday, December 12th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $5.41.
A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in Endologix by 5.6% in the second quarter. Vanguard Group Inc. now owns 6,638,302 shares of the medical instruments supplier’s stock valued at $32,262,000 after purchasing an additional 353,233 shares during the period. Redmile Group LLC raised its holdings in shares of Endologix by 134.4% in the 2nd quarter. Redmile Group LLC now owns 6,368,299 shares of the medical instruments supplier’s stock valued at $30,950,000 after buying an additional 3,650,905 shares during the period. State Street Corp raised its holdings in shares of Endologix by 11.5% in the 2nd quarter. State Street Corp now owns 1,951,432 shares of the medical instruments supplier’s stock valued at $9,483,000 after buying an additional 201,700 shares during the period. Northern Trust Corp raised its holdings in shares of Endologix by 5.0% in the 2nd quarter. Northern Trust Corp now owns 1,104,943 shares of the medical instruments supplier’s stock valued at $5,369,000 after buying an additional 52,755 shares during the period. Finally, Stephens Inc. AR raised its holdings in shares of Endologix by 10.5% in the 2nd quarter. Stephens Inc. AR now owns 845,016 shares of the medical instruments supplier’s stock valued at $4,107,000 after buying an additional 80,328 shares during the period.
COPYRIGHT VIOLATION WARNING: “-$0.22 EPS Expected for Endologix, Inc. (ELGX) This Quarter” was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.com-unik.info/2017/12/26/0-22-eps-expected-for-endologix-inc-elgx-this-quarter.html.
Endologix Company Profile
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.